VTGN

Company Overview — What Does Vistagen Therapeutics, Inc. Do?

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California. Vistagen Therapeutics, Inc. (VTGN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Shawn K. Singh and employs approximately 40 people, headquartered in SOUTH SAN FRANCISCO, California. With a market capitalization of $24M, VTGN is one of the notable companies in the Healthcare sector.

Vistagen Therapeutics, Inc. (VTGN) Stock Rating — Avoid (April 2026)

As of April 2026, Vistagen Therapeutics, Inc. receives a Avoid rating with a composite score of 20.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.VTGN ranks #4,163 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Vistagen Therapeutics, Inc. ranks #735 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VTGN Stock Price and 52-Week Range

Vistagen Therapeutics, Inc. (VTGN) currently trades at $0.57. The stock gained $0.02 (3.1%) in the most recent trading session. The 52-week high for VTGN is $5.14, which means the stock is currently trading -88.9% from its annual peak. The 52-week low is $0.43, putting the stock 33.3% above its annual trough. Recent trading volume was 290K shares, suggesting relatively thin trading activity.

Is VTGN Overvalued or Undervalued? — Valuation Analysis

Vistagen Therapeutics, Inc. (VTGN) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.42x, versus the sector average of 2.75x. The price-to-sales ratio is 20.43x, compared to 1.66x for the average Healthcare stock.

At current multiples, Vistagen Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Vistagen Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Vistagen Therapeutics, Inc. (VTGN) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -132.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -103.8% versus the sector average of -33.1%.

On a margin basis, Vistagen Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -6790.5% (sector: -66.1%). Net profit margin stands at -6492.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 65.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VTGN Debt, Balance Sheet, and Financial Health

Vistagen Therapeutics, Inc. has a debt-to-equity ratio of 28.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.67x, indicating strong short-term liquidity.

VTGN has a beta of 1.02, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Vistagen Therapeutics, Inc. is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Vistagen Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Vistagen Therapeutics, Inc. reported revenue of $1M and earnings per share (EPS) of $-0.45. Net income for the quarter was $-68M. Operating income came in at $-71M.

In Q3 2026, Vistagen Therapeutics, Inc. reported revenue of $303,000 and earnings per share (EPS) of $-0.45. Net income for the quarter was $-19M. Revenue grew 29.5% year-over-year compared to Q3 2025. Operating income came in at $-20M.

In Q2 2026, Vistagen Therapeutics, Inc. reported revenue of $258,000 and earnings per share (EPS) of $-0.54. Net income for the quarter was $-19M. Revenue grew 41.0% year-over-year compared to Q2 2025. Operating income came in at $-20M.

In Q1 2026, Vistagen Therapeutics, Inc. reported revenue of $244,000 and earnings per share (EPS) of $-0.47. Net income for the quarter was $-15M. Revenue grew 190.5% year-over-year compared to Q1 2025. Operating income came in at $-16M.

Over the past 8 quarters, Vistagen Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $84,000 to $1M. Investors analyzing VTGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VTGN Dividend Yield and Income Analysis

Vistagen Therapeutics, Inc. (VTGN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VTGN Momentum and Technical Analysis Profile

Vistagen Therapeutics, Inc. (VTGN) has a momentum factor score of 11/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 57/100 reflects moderate short selling activity.

VTGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Vistagen Therapeutics, Inc. (VTGN) ranks #735 out of 838 stocks based on the Blank Capital composite score. This places VTGN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VTGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VTGN vs S&P 500 (SPY) comparison to assess how Vistagen Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

VTGN Next Earnings Date

No upcoming earnings date has been announced for Vistagen Therapeutics, Inc. (VTGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VTGN? — Investment Thesis Summary

The quantitative profile for Vistagen Therapeutics, Inc. suggests caution. The quality score of 18/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 11/100, a headwind for near-term performance. High volatility (stability score 29/100) increases portfolio risk.

In summary, Vistagen Therapeutics, Inc. (VTGN) earns a Avoid rating with a composite score of 20.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VTGN stock.

Related Resources for VTGN Investors

Explore more research and tools: VTGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VTGN head-to-head with peers: VTGN vs AZN, VTGN vs SLGL, VTGN vs VMD.